BioCentury
ARTICLE | Clinical News

ACE-083: Phase I started

October 20, 2014 7:00 AM UTC

Acceleron began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate single intramuscular injections of 50, 100 and 200 mg ACE-083 and 2 doses of 100 and 200 mg ACE-083 ...